2025/11/19 by Luiz Guilherme Darrigo, Gisele Loth, Virginio Climaco de Araujo Fernandes +3 · 1 voice
Biochemistry, Genetics and Molecular Biology · Medicine · #Acute Myeloid Leukemia Research #Blood disorders and treatments #Hematopoietic Stem Cell Transplantation
paper · pdf · doi:10.46765/2675-374x.2025v6n1e312
openalex created_date 2025/11/19 · openalex publication_date 2025/11/19 · openalex updated_date 2026/06/11
Acquired severe aplastic anemia is a rare, life-threatening condition characterized by pancytopenia and hypocellularity of the bone marrow. It shows a bimodal age distribution, with approximately 70–80% of cases classified as idiopathic. Recent advances in hematopoietic cell transplantation, immunosuppressive therapy, biological agents, and supportive care have greatly improved survival rates, reaching a 95% cure rate. Differential diagnoses include refractory cytopenia of childhood, inherited bone marrow failure syndromes, and other blood disorders. The aim of this article was to update the Brazilian consensus previously published by the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation in 2021, highlighting the latest developments in the treatment and monitoring of severe aplastic anemia patients undergoing hematopoietic cell transplantation.